At BIOTRONIK, patient well-being is our top priority and has been for over 60 years. BIOTRONIK is a leading global medical technology company with products and offerings that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation therapies. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries across the Americas, EMEA (Europe, the Middle East, and Africa), and Asia-Pacific.

Left Bundle Branch Area Pacing Lead Delivery System

Proven Performance. Reliable Results.

• The first and only FDA-approved stylet-driven lead and dedicated delivery catheter combination for LBBAP1,2*
• Proven in 80,000 patients worldwide and more than 30 clinical studies to date.1

1. Data on file. As of July 2024.
2. BIOTRONIK Solia S, Selectra 3D technical manuals. Abbott CPS Locator 3D manual; Boston Scientific Ingevity+, SSPC Catheter manuals
* 45 cm length not indicated for LBBAP

Left Bundle Branch Area Delivery System >>

LBBAP Brochure >>

DX Technology

The only single-lead ICD system providing true atrial sensing

• DX ICDs increase the likelihood of detecting atrial arrhythmias early compared to single-chamber ICDS,¹ helping you to identify patients at risk and enabling prompt, appropriate patient management.
• DX Technology allows you to assess and reliably monitor² AF burden as well as subsequent disease progression over time.
• Since DX Technology can detect and monitor AF burden, appropriate therapy can be initiated in a timely manner for improved clinical outcomes.3,4

1. Thomas G, et al. Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter-defibrillator systems: Results of the SENSE trial. Journal of Cardiovascular Electrophysiology, Volume 30, Issue 10, October 2019, Pages 1994–2001.
2. Hindricks G, Theuns DA, Bar-Lev D, et al. Ability to remotely monitor atrial high-rate episodes using a single-chamber implantable cardioverter-defibrillator with a floating atrial sensing dipole. EP Europace, 2023, 00, 1-10.
3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, Volume 42, Issue 5, 1 February 2020, Pages 373–498.
4. January C, Wann LS, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140:e125-e151.

DX Technology >>

DX Technology Presentation >>

MATRIX Study Brochure >>

BIOMONITOR IV Implantable Cardiac Monitor with SmartECG

Intelligence. Confidence. Clarity.

• BIOMONITOR IV comes with SmartECG, an intelligent system that powers AI and advanced algorithms, designed to reduce the number of false positive episodes for Atrial Fibrillation, Bradycardia, Tachycardia, and Pause. This allows you to focus on actionable events and spend more time on patient care.
• BIOTRONIK Home Monitoring offers indication-based templates, enhanced automaticity and intuitive reports to deliver efficient access to optimized clinical data and insights. 

BIOMONITOR IV >>

BIOMONITOR IV Brochure >>